2,3-Bis(4-hydroxy-3-methoxyphenyl)prop-2-enal

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2,3-Bis(4-hydroxy-3-methoxyphenyl)prop-2-enal
• 英文别名: 2,3-bis(4-hydroxy-3-methoxyphenyl)prop-2-enal
• 化学式: C₁₇H₁₆O₅
• 分子量: 300.3
• InChiKey: IDJCIWTUMGTOMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Method for treating a protozoal infection
  申请人：Reid Christopher Brian

  公开号：US10561650B2

  公开（公告）日：2020-02-18

  A method for reducing motility and number of L. donovani cells, said method comprising contacting the L. donovani cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the L. donovani cells.

  一种降低唐诺瓦尼氏菌细胞活力和数量的方法，所述方法包括将唐诺瓦尼氏菌细胞与有效量的组合物接触，所述组合物包括甲硝唑和伊曲康唑的组合，其中有效量足以降低唐诺瓦尼氏菌细胞的活力。
• Natural preservatives and antimicrobial agents, including compositions thereof
  申请人：Unigen, Inc.

  公开号：US10780173B2

  公开（公告）日：2020-09-22

  Compositions are disclosed herein that comprise a mixture of at least one Albizia extract and a Magnolia extract. In some embodiments, the composition comprises a mixture of at least one Albizia extract enriched for one or more macrocyclic alkaloids and at least one Magnolia extract enrich for one or more lignans.

  本文公开的组合物包括至少一种白花蛇舌草提取物和一种厚朴提取物的混合物。在某些实施方案中，组合物包括至少一种富含一种或多种大环生物碱的白花蛇舌草提取物和至少一种富含一种或多种木脂素的厚朴提取物的混合物。
• NATURAL PRESERVATIVES AND ANTIMICROBIAL AGENTS, INCLUDING COMPOSITIONS THEREOF
  申请人：Unigen, Inc.

  公开号：EP3373946A1

  公开（公告）日：2018-09-19
• US20140271923A1
  申请人：——

  公开号：US20140271923A1

  公开（公告）日：2014-09-18
• METHOD FOR TREATING A PROTOZOAL INFECTION
  申请人：REID Christopher Brian

  公开号：US20160354370A1

  公开（公告）日：2016-12-08

  Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.